Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The efficacy and potential limitations of molecular residual disease (MRD) detection urgently need to be fully elucidated in a larger population of non-small cell lung cancer (NSCLC). We enrolled 261 patients with stages I to III NSCLC who underwent definitive surgery, and 913 peripheral blood samples were successfully detected by MRD assay. Within the population, only six patients (3.2%) with longitudinal undetectable MRD recurred, resulting in a negative predictive value of 96.8%. Longitudinal undetectable MRD may define the patients who were cured. The peak risk of developing detectable MRD was approximately 18 months after landmark detection. Correspondingly, the positive predictive value of longitudinal detectable MRD was 89.1%, with a median lead time of 3.4 months. However, brain-only recurrence was less commonly detected by MRD (n = 1/5, 20%). Further subgroup analyses revealed that patients with undetectable MRD might not benefit from adjuvant therapy. Together, these results expound the value of MRD in NSCLC. SIGNIFICANCE: This study confirms the prognostic value of MRD detection in patients with NSCLC after definitive surgery, especially in those with longitudinal undetectable MRD, which might represent the potentially cured population regardless of stage and adjuvant therapy. Moreover, the risk of developing detectable MRD decreased stepwise after 18 months since landmark detection. This article is highlighted in the In This Issue feature, p. 1599.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Circulating tumor DNA (ctDNA) detection based on next-generation sequencing (NGS) is increasingly employed to monitor minimal residual disease (MRD) in various cancers, including acute myeloid leukemia (AML), breast cancer, and lung cancer.5, 6, 7”
From Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531 · cited 1×
“, DNMT3A, TET2, and PPM1D), as reported in the previous studies (25, 26).”
ResultLung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Tracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349 · cited 2×
“Moreover, the tissue local sampling itself cannot represent the whole picture of the tumor, as intratumoral heterogeneity may also contribute to the inconsistency (30).”
BackgroundAn ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220 · cited 4×
“Because cerebrospinal fluid (CSF) has been proven to be a comparable or superior detection medium to peripheral blood for central nervous system primary or metastatic tumors (21–23), high-depth ctDNA testing of CSF may be worthwhile, as is the case for the CAPP-seq technique on urine (uCAPP-seq; ref.”
MethodInfluentialPhylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The TRACERx consortium, Abbosh, C., The PEACE consortium, Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D. A., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,874
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Wu, Y.-L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S.-W., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,798 · cited 1×
“Encouragingly, substantial progress has been made since the introduction of tyrosine kinase inhibitors and immune-checkpoint inhibitors (ICI), as reported in the ADAURA and IMpower 010 trials (4, 5).”
BackgroundFelip, E., Altorki, N., Zhou, C., Csőszi, T., Vynnychenko, I., Goloborodko, O., Luft, A., Akopov, A., Martinez-Marti, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,486 · cited 1×
“Encouragingly, substantial progress has been made since the introduction of tyrosine kinase inhibitors and immune-checkpoint inhibitors (ICI), as reported in the ADAURA and IMpower 010 trials (4, 5).”
BackgroundLiquid biopsy and minimal residual disease - latest advances and implications for cure
Pantel, K., & Alix-Panabières, C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0187-3 · Cited by 1,110
Integrated digital error suppression for improved detection of circulating tumor DNA
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3520 · Cited by 1,099
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,072 · cited 1×
“Landmark (0,6) (6,12) (12,18) (18,24) (24,30) >30 0 50 100”
De Mattos-Arruda, L., Mayor, R., Ng, C. K. Y., Weigelt, B., Martínez-Ricarte, F., Torrejon, D., Oliveira, M., Arias, A., Raventos, C., Tang, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9839 · Cited by 865
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Razavi, P., Li, B. T., Brown, D. N., Jung, B., Hubbell, E., Shen, R., Abida, W., Juluru, K., De Bruijn, I., Hou, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0652-7 · Cited by 769 · cited 1×
“, DNMT3A, TET2, and PPM1D), as reported in the previous studies (25, 26).”
ResultctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Powles, T., Assaf, Z. J., Davarpanah, N., Banchereau, R., Szabados, B. E., Yuen, K. C., Grivas, P., Hussain, M., Oudard, S., Gschwend, J. E., et al. (2021) · Nature · doi:10.1038/s41586-021-03642-9 · Cited by 646 · cited 1×
“The question that follows is this: What is the efficacy of adjuvant therapy for patients with detectable and undetectable MRD? In other words, can patients with undetectable MRD be guided to avoid adjuvant therapy? In a phase III randomized trial (IMvigor010) by Powles and colleagues (16), adjuvant atezolizumab was co…”
BackgroundEarly stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection
Abbosh, C., Birkbak, N. J., & Swanton, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0058-3 · Cited by 450 · cited 1×
“4% in the overall population, which is relatively lower than that reported in published studies (15).”
ResultGenome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring
Zviran, A., Schulman, R. C., Shah, M., Hill, S. T. K., Deochand, S., Khamnei, C. C., Maloney, D., Patel, K., Liao, W., Widman, A. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0915-3 · Cited by 434
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
Garcia-Murillas, I., Chopra, N., Comino-Méndez, I., Beaney, M., Tovey, H., Cutts, R. J., Swift, C., Kriplani, D., Afentakis, M., Hrebien, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1838 · Cited by 410
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Yoo, C. H., Gojenola, L., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0011-0 · Cited by 365
Thompson, J. C., Yee, S. S., Troxel, A. B., Savitch, S. L., Fan, R., Balli, D., Lieberman, D. B., Morrissette, J. D., Evans, T. L., Bauml, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1231 · Cited by 325
Li, Y. S., Jiang, B. Y., Yang, J. J., Zhang, X. C., Zhang, Z., Ye, J. Y., Zhong, W. Z., Tu, H. Y., Chen, H. J., Wang, Z., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy009 · Cited by 300
Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
Zhang, Y., Yao, Y., Xu, Y., Li, L., Gong, Y., Zhang, K., Zhang, M., Guan, Y., Chang, L., Xia, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20162-8 · Cited by 300 · cited 1×
“5 Mbp of the genome and targeting 1,021 cancerrelated genes was used for hybridization enrichment (31).”
MethodDynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
Qiu, B., Guo, W., Zhang, F., Lv, F., Ji, Y., Peng, Y., Chen, X., Bao, H., Xu, Y., Shao, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27022-z · Cited by 276
Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
Dudley, J. C., Schroers-Martin, J., Lazzareschi, D. V., Shi, W. Y., Chen, S. B., Esfahani, M. S., Trivedi, D., Chabon, J. J., Chaudhuri, A. A., Stehr, H., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0825 · Cited by 253 · cited 1×
“Landmark (0,6) (6,12) (12,18) (18,24) (24,30) >30 0 50 100”
Wu, Y.-L. L. C., John, T., Grohé, C., Majem, M., Goldman, J. W., Kim, S., Kato, T., Лактионов, К. К., Vũ, H. V., Wang, Z., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.014 · Cited by 167
Chae, Y. K., & Oh, M. S. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.022 · Cited by 150
Seoane, J., De Mattos-Arruda, L., Le Rhun, E., Bardelli, A., & Weller, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy544 · Cited by 144
Pechoux, C. L., Pourel, N., Barlési, F., Finn, C. F., Lerouge, D., Zalcman, G., Antoni, D., Lamezec, B., Nestle, U., Boisselier, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2280 · Cited by 94
Xu, L., Xi, J., Zhong, W., Mao, W., Wu, L., Shen, Y., Liu, Y., Chen, C., Cheng, Y., Xu, L., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.020 · Cited by 71 · cited 1×
“Dynamic hazard rates of detectable MRD or disease recurrences were assessed to provide a temporal pattern of MRD monitoring; methods have been described in detail elsewhere (33).”
MethodGuo, Q., Wang, J., Xiao, J., Wang, L., Hu, X., Yu, W., Song, G., Lou, J., & Chen, J. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0875-0 · Cited by 66
Jiang, J., Adams, H.-P., Yao, L., Yaung, S. J., Lal, P. G., Balasubramanyam, A., Fuhlbrück, F., Tikoo, N., Lovejoy, A. F., Froehler, S., et al. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.10.013 · Cited by 65
Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma
Lin, G., Li, C., Li, P. S., Fang, W. Z., Xu, H., Gong, Y. H., Zhu, Z., Hu, Y., Liang, W., Chu, Q., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.014 · Cited by 57 · cited 1×
“Detailed variant calling and filter strategies were reported previously (32).”
BackgroundCHOUAID, C., Danson, S. J., Andreas, S., Siakpere, O., Benjamin, L., Ehneß, R., Dramard-Goasdoue, M.-H., Barth, J., Hoffmann, H., Potter, V. A., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.042 · Cited by 43
Burdett, S., Rydzewska, L. H. M., Tierney, J. F., & Fisher, D. J. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.005 · Cited by 38
Buck, P. O., Saverno, K. R., Miller, P. J., Arondekar, B. V., & Walker, M. S. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.010 · Cited by 31
Cited by
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohé, C., Wang, J., Goldman, J. W., Lu, S., Su, W.-C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304594 · Cited by 672
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 672
“For example, first generation assays can only detect MRD at the post-treatment landmark in approximately one third of early-stage NSCLC and half of colon cancer patients destined to develop recurrence 159,162,197,204– 206 .”
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Wu, Y.-L., Dziadziuszko, R., Ahn, J. S., Barlesi, F., Nishio, M., Lee, D. H., Lee, J.-S., Zhong, W., Horinouchi, H., Mao, W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2310532 · Cited by 431
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Abbosh, C., Frankell, A. M., Harrison, T., Kisistok, J., Garnett, A., Johnson, L., Veeriah, S., Moreau, M., Chesh, A., Chaunzwa, T. L., et al. (2023) · Nature · doi:10.1038/s41586-023-05776-4 · Cited by 382
Self-citationMountzios, G., Remon, J., Hendriks, L. E. L., García-Campelo, R., Rolfo, C., Van Schil, P., Forde, P. M., Besse, B., Subbiah, V., Reck, M., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00794-7 · Cited by 199
Metadata
- Authors
- Zhang, J.-T., Liu, S.-Y., Gao, W., Liu, S.-Y. M., Yan, H.-H., Ji, L., Chen, Y., Gong, Y., Lu, H.-L., Lin, J.-T., Yin, K., Jiang, B.-Y., Nie, Q., Liao, R.-Q., Dong, S., Guan, Y., Dai, P., Zhang, X.-C., Yang, J.-J., Tu, H.-Y., Xia, X., Yi, X., Zhou, Q., Zhong, W.-Z., Yang, X.-N., & Wu, Y.-L.
- Affiliations
- Guangdong Academy of Medical Sciences (CN)
- Jinan University (CN)
- 2Geneplus-Beijing Institute, Beijing, China.
- Corresponding author
- Yang, Xue-Ning
- Wu, Yi-Long
- ORCID
- Venue
- Cancer Discovery
- Published
- 2022-05-11
- Volume
- 12
- Issue
- 7
- Pages
- 1690-1701
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC9394392
- OpenAlex
- W4280569356
- Cited by
- 228
- References
- 33
- Citations by year
- 2026: 35 · 2025: 58 · 2024: 61 · 2023: 61 · 2022: 13
- FWCI
- 20.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Guangdong Science and Technology Department Translational Medicine in Lung Cancer (2017B030314120)
- Leading Medical Talents in Guangdong Province (KJ012019426)
- Guangdong Provincial People's Hospital Young Talent Project (GDPPHYTP201902, KY012021189)
- China Postdoctoral Science Foundation (2021M701422)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- molecular residual disease, non-small cell lung cancer, localized lung cancer, recurrence prediction, negative predictive value, adjuvant therapy, prognostic factors, postoperative follow-up
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Prognosis, Neoplasm, Residual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.